The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000919314p
Ethics application status
Help: Ethics application status
Not yet submitted
Date submitted
Help: Date submitted
17/06/2026
Date registered
Help: Date registered
27/07/2026
Date last updated
Help: Date last updated
27/07/2026
Date data sharing statement initially provided
Help: Data sharing statement date
27/07/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
CRONOS-1: Transbronchial Cryo-Assisted Hybrid RadioFrequency
Ablation of Malignant Pulmonary Nodules: An immediate Treat-and-
resect Study
Scientific title
CRONOS-1: Transbronchial Cryo-Assisted Hybrid RadioFrequency
Ablation of Malignant Pulmonary Nodules: An immediate Treat-and-
resect Study
Additional trial identifiers [1] 317600 0
Nil Known
Universal Trial Number (UTN)
Trial acronym
CRONOS-1
Related trial records

Health condition
Health condition(s) studied:
malignant pulmonary nodules 342371 0
Condition category
Condition code
Respiratory 338501 338501 0 0
Other respiratory disorders / diseases
Surgery 338502 338502 0 0
Surgical techniques

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Participants with histologically confirmed malignant pulmonary nodules less than or equal to 25mm undergo transbronchial cryo-assisted radiofrequency ablation (cryoRFA) using the HybridTherm® bipolar eTip® probe (OD 1.9 mm, length 1.25 m; Erbe Elektromedizin GmbH) immediately prior to planned standard-of-care surgical resection, under the same general anaesthetic. The interventional Pulmonologist will be completing the intervention.

The procedure is performed via robotic-assisted bronchoscopy (RAB) with Cone-Beam CT (CBCT) or digital tomography (DT) guidance. The HybridTherm® probe is navigated to the target nodule and ablation is performed in cryoRFA mode (CO2-cooled bipolar RF delivery). Ablation duration is individualised based on lesion size and location, ranging from 5 to 15 minutes per session. A tipCUT mode is used for transbronchial access; trackCOAG and softCOAG modes are available for procedural haemostasis. The probe position and estimated ablation zone are confirmed by intra-procedural advanced imaging (CBCT/DT) prior to and at the conclusion of energy delivery.
Following ablation, participants proceed immediately to surgical resection of the ablated nodule under the same anaesthetic. There are no additional study visits beyond the Day 1 follow-up. The total participant duration is approximately 4 weeks (from screening to Day 1 follow-up).
Intervention code [1] 334422 0
Treatment: Devices
Intervention code [2] 334423 0
Treatment: Surgery
Description of the comparator or control
No comparator. This is a single-arm, treat-and-resect feasibility study. All participants receive the investigational intervention (cryoRFA ablation) immediately prior to their standard-of-care surgical resection.
Control group
Uncontrolled

Outcomes
Primary outcome [1] 345790 0
Successful device use: completion of ablation with the HybridTherm® system with investigator confirmation that the ablation zone achieved sufficient coverage.
Timepoint [1] 345790 0
Day 0 – at the conclusion of the cryoRFA ablation procedure, prior to surgical resection (intra-operative).
Primary outcome [2] 345791 0
Potential AEs and SAEs include: Post-treatment acute inflammatory Response (PAIR), Pneumothorax, Pneumonitis, Pneumonia, respiratory failure, haemoptysis, significant hemoptysis, however these are unlikekly to affect the course of patient care as they often manifest post-procedure. Number of immediate Serious Adverse Events (SAEs) related to the investigational device and/or ablation procedure such as adverse device effects such as; insufficient or inadequate instructions for use, deployment, implantation, installation, or operation, or any malfunction of the investigational medical device, unanticipated serious device effects which by its nature, incidence, severity, or outcome has not been identified in the current version of the risk analysis report. Device Deficiency defined as an inadequacy of a medical device related to its identity, quality, durability, reliability, safety, or performance, such as malfunction, misuse or use error, and inadequate labeling (Medical Device Regulation (EU) 2017/745).
Timepoint [2] 345791 0
Day 0 (from commencement of ablation procedure) through Day 1 follow-up (24 hours post-procedure).
Secondary outcome [1] 463309 0
Potential AEs and SAEs include: Post-treatment acute inflammatory Response (PAIR), Pneumothorax, Pneumonitis, Pneumonia, respiratory failure, haemoptysis, significant hemoptysis, however these are unlikekly to affect the course of patient care as they often manifest post-procedure. Number of immediate Serious Adverse Events (SAEs) related to the investigational device and/or ablation procedure such as adverse device effects such as; insufficient or inadequate instructions for use, deployment, implantation, installation, or operation, or any malfunction of the investigational medical device, unanticipated serious device effects which by its nature, incidence, severity, or outcome has not been identified in the current version of the risk analysis report. Device Deficiency defined as an inadequacy of a medical device related to its identity, quality, durability, reliability, safety, or performance, such as malfunction, misuse or use error, and inadequate labeling (Medical Device Regulation (EU) 2017/745). SAEs include any adverse event (AE) that: (a) led to death, (b) led to serious deterioration in the health of the participant, which either resulted in: • life-threatening illness or injury, or • a permanent impairment of a body structure or a body function, or • Inpatient or prolonged hospitalisation, or • medical or surgical intervention to prevent life-threatening illness or injury or permanent impairment to a body structure or a body function, Planned hospitalisation for a pre-existing condition, or a procedure required by the CIP, without serious deterioration in health, is not considered a serious adverse event. Any adverse event (AE) that: (a) led to death, (b) led to serious deterioration in the health of the participant, which either resulted in: • life-threatening illness or injury, or • a permanent impairment of a body structure or a body function, or • Inpatient or prolonged hospitalisation, or • medical or surgical intervention to prevent life-threatening illness or injury or permanent impairment to a body structure or a body function, Planned hospitalisation for a pre-existing condition, or a procedure required by the CIP, without serious deterioration in health, is not considered a serious adverse event.
Timepoint [1] 463309 0
Day 0 (from enrolment at ablation procedure) through Day 1 post-procedure follow-up.
Secondary outcome [2] 463310 0
Histopathologic Complete Response (hpCR) rate: presence or absence of viable tumour cells within the intended ablation zone.
Timepoint [2] 463310 0
Post-operative: histopathological assessment of resected specimen, reported following surgical resection on Day 0. Results available per standard pathology turnaround.
Secondary outcome [3] 463311 0
Estimated percentage of tumour necrosis within the ablation zone.
Timepoint [3] 463311 0
Post-operative: derived from histopathological assessment of the resected specimen (Day 0 surgery, reported per standard pathology workflow).
Secondary outcome [4] 463312 0
Macroscopic and microscopic dimensions of the ablation zone and necrotic area (mm). This is a composite secondary outcome.
Timepoint [4] 463312 0
Post-operative: from histopathological analysis of the surgically resected specimen (Day 0).
Secondary outcome [5] 463313 0
Histopathological effects of ablation on non-malignant structures within the ablation zone (alveolar tissue, airways, blood vessels, neurovascular structures). This is a composite outcome.
Timepoint [5] 463313 0
Post-operative: from histopathological analysis of the resected specimen (Day 0).
Secondary outcome [6] 463314 0
Estimated ablation zone size (mm) derived from final intra-procedural imaging.
Timepoint [6] 463314 0
Day 0 – intra-operative, at the conclusion of cryoRFA energy delivery and after removal of the ablation catheter.
Secondary outcome [7] 463315 0
Total ablation time (minutes).
Timepoint [7] 463315 0
Day 0 – recorded intra-operatively during the ablation procedure.
Secondary outcome [8] 463316 0
Number of cryoRFA activations (energy delivery cycles).
Timepoint [8] 463316 0
Day 0 – recorded intra-operatively during the ablation procedure.
Secondary outcome [9] 463317 0
Electrical parameters of energy delivered during the procedure (impedance changes, energy delivery profile, ablation cycle duration). This is a composite outcome.
Timepoint [9] 463317 0
Day 0 – recorded intra-operatively during the ablation procedure (where technically retrievable from device).
Secondary outcome [10] 463318 0
Number of probe repositionings within the target lesion.
Timepoint [10] 463318 0
Day 0 – recorded intra-operatively during the ablation procedure.
Secondary outcome [11] 463319 0
Estimated ablation zone size on intra-procedural imaging (CBCT/DT)
Timepoint [11] 463319 0
Post-study data analysis phase (following collection of all Day 0 procedural and histopathological data). Anticipated: January–July 2027.
Secondary outcome [12] 463320 0
Tumour characteristics recorded from standard-of-care pre-procedural imaging including: location (lobe), maximum tumour diameter (mm) and distance from tumour margin to pleura (mm). This is a composite outcome.
Timepoint [12] 463320 0
Post-study data analysis phase (following collection of all procedural and imaging data). Anticipated: January–July 2027.
Secondary outcome [13] 463795 0
Histologically observed necrosis dimensions (mm)
Timepoint [13] 463795 0
Post-study data analysis phase (following collection of all procedural and imaging data). Anticipated: January–July 2027.
Secondary outcome [14] 463796 0
Tumour characteristics recorded from standard-of-care pre-procedural imaging including: location (lobe), maximum tumour diameter (mm) and distance from tumour margin to pleura (mm). This is a composite outcome.
Timepoint [14] 463796 0
Post-study data analysis phase (following collection of all procedural and imaging data). Anticipated: January–July 2027.

Eligibility
Key inclusion criteria
1. Age equal to or greater than 18-years-old
2. Ability to read, understand, and sign the participant’s Informed Consent Form (ICF)
3. Histologically confirmed malignant pulmonary nodule of less than or equal to 25mm in maximum diameter in size and planned for surgical resection as per MDT consensus
4. MDT consensus recommendation for surgical resection of the target nodule
5. Suitable candidate for surgical resection of the target nodule
6. More than 20 mm between the calculated intended ablation zone and any critical structures (pleura, large vessels and main bronchi).
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
1. Pregnant or nursing (breastfeeding)
2. Central tumours abutting vital structures (main bronchus, pulmonary artery, esophagus, trachea)
3. Clinical management relying on further post-surgical histopathological information e.g for molecular or PDL-1 studies.
4. Thoracic electronic implants (e.g., pacemakers, ICDs)
5. Uncorrectable coagulopathy or platelet count less than or equal to 50,000/mm3
6. Severe, uncontrolled comorbidities
7. Active systemic infection
8. Prior radiation therapy in the intended ablation zone
9. Recent Investigational therapy within the last 30 days
10. Tumours associated with atelectasis, obstructive pneumonitis, pleural effusion, or fibrosis
11. Investigators determine that study participation poses a safety risk
12. Any comorbidities judged by the investigators to be contraindicated for bronchoscopy
13. Subject deemed unsuitable for study participation by the Investigator for any reason

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Other design features
Phase
Not Applicable
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW

Funding & Sponsors
Funding source category [1] 322154 0
Commercial sector/Industry
Name [1] 322154 0
Erbe Elektromedizin GmbH
Country [1] 322154 0
Germany
Primary sponsor type
University
Name
Macquarie University
Address
Country
Australia
Secondary sponsor category [1] 325051 0
None
Name [1] 325051 0
Address [1] 325051 0
Country [1] 325051 0

Ethics approval
Ethics application status
Not yet submitted
Ethics committee name [1] 320684 0
Macquarie University Human Research Ethics Committee Medical Sciences
Ethics committee address [1] 320684 0
Ethics committee country [1] 320684 0
Australia
Date submitted for ethics approval [1] 320684 0
10/08/2026
Approval date [1] 320684 0
Ethics approval number [1] 320684 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 151278 0
Prof Tajalli Saghaie
Address 151278 0
2 Technology Place, Macquarie University, Macquarie Park, Sydney, New South Wales, Australia, 2113
Country 151278 0
Australia
Phone 151278 0
+61 2 9812 3548
Fax 151278 0
Email 151278 0
Contact person for public queries
Name 151279 0
Tajalli Saghaie
Address 151279 0
2 Technology Place, Macquarie University, Macquarie Park, Sydney, New South Wales, Australia, 2113
Country 151279 0
Australia
Phone 151279 0
+61 2 9812 3548
Fax 151279 0
Email 151279 0
Contact person for scientific queries
Name 151280 0
Tajalli Saghaie
Address 151280 0
2 Technology Place, Macquarie University, Macquarie Park, Sydney, New South Wales, Australia, 2113
Country 151280 0
Australia
Phone 151280 0
+61 2 9812 3548
Fax 151280 0
Email 151280 0

Data sharing statement
Will the study consider sharing individual participant data?
No
No IPD sharing reason/comment: given the very small sample size (n equal to 5), individual-level data sharing is not planned to protect participant confidentiality. De-identified aggregate data will be reported in publications.



What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.